The Technical Analyst
Aprea Therapeutics Inc [APRE]
Exchange: NasdaqGS Sector: Healthcare Industry: Biotechnology
Aprea Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-7.98% $1.095
Last updated: 16 May 2022 @ 11:03 am
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 24.06 mill |
| EPS: | -1.744 |
| P/E: | 0.000 |
| Earnings Date: | May 16, 2022 |
| SharesOutstanding: | 21.97 mill |
| Avg Daily Volume: | 0.310 mill |
| RATING 2022-05-13 |
|---|
| B |
| Neutral |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/20 | 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$3.62 (230.18%) $2.52 |
| Date: 2022-05-16 |
| True Range Average |
|---|
|
+/- $0.137 ( +/- 11.51%) Range: 1.053 - 1.327 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-03-10 | Abrahmsen Lars B. | Buy | 100 000 | Stock Option (right to Buy) |
| 2022-03-10 | Abrahmsen Lars B. | Buy | 24 700 | Common Stock |
| 2022-03-10 | Attar Eyal C. | Buy | 185 900 | Stock Option (right to Buy) |
| 2022-03-10 | Attar Eyal C. | Buy | 42 900 | Common Stock |
| 2022-03-10 | Coiante Scott M | Buy | 185 900 | Stock Option (right to Buy) |
| INSIDER POWER |
|---|
| 41.80 |
| Last 100 transactions |
| Buy: 2 827 962 | Sell: 3 658 227 |
Forecast:
12:42 - $1.129
Live Trading Signals (every 1 min)
Forecast
1: 11:12 - $1.113
Forecast 2: 12:02 - $1.118
Forecast 3: 12:42 - $1.129
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.095 (-7.98% ) |
| Volume | 0.143 mill |
| Avg. Vol. | 0.310 mill |
| % of Avg. Vol | 46.21 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For APRE
300 Signals | Accuracy: 16.33% | Accuracy Buy: 12.00% | Accuracy Sell: 20.67%
Avg return buy: -0.57 % | Avg return sell: 0.35 %
$1 invested is now $0.42 or -58.05% since 20-04-22
| Date | Signal | @ | Closed | % | May 16 - 09:38 | sell | $1.174 | N/A | Active |
|---|---|---|---|---|
| May 16 - 09:32 | buy | $1.190 | $1.174 @ May 16 - 09:37 | -1.34% |
| May 13 - 16:01 | sell | $1.190 | $1.190 @ May 16 - 09:31 | 0.00% |
| May 13 - 15:46 | buy | $1.190 | $1.190 @ May 13 - 15:59 | 0.00% |
| May 13 - 15:10 | sell | $1.200 | $1.190 @ May 13 - 15:45 | -0.83% |
| May 13 - 14:54 | buy | $1.190 | $1.200 @ May 13 - 15:10 | 0.84% |
| May 13 - 14:34 | sell | $1.170 | $1.190 @ May 13 - 14:53 | 1.71% |
| May 13 - 14:29 | buy | $1.177 | $1.170 @ May 13 - 14:33 | -0.62% |
| May 13 - 14:04 | sell | $1.170 | $1.177 @ May 13 - 14:28 | 0.62% |
| May 13 - 13:51 | buy | $1.177 | $1.170 @ May 13 - 14:03 | -0.62% |
APRE
Aprea Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Boston, Massachusetts and currently employs 14 full-time employees. The firm is focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its lead product candidate, APR-246, is a small molecule p53 reactivator that is being developed for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). APR-246 product candidate is designed to be administered intravenously and forms the active moiety, 2-methylene-quinuclidin-3-one (MQ), under physiological conditions. Its second product candidate, APR-548, is a p53 reactivator. APR-548 is being developed in an oral dosage form.
Latest Press Releases
2022-05-16 09:21:00 - Press Release
Aprea Therapeutics Announces Acquisition Of Atrin Pharmaceuticals Inc. And Reports First Quarter 2022 Financial Results
Boston, may 16, 2022 (globe newswire) -- aprea therapeutics, inc. (nasdaq: apre), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting dna damage response pathways today announced that it has acquired atrin pharmaceuticals inc. (“atrin”) and reported financial results for the three months ended march 31, 2022.
2022-03-15 16:15:00 - Press Release
Aprea Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Update On Business Operations
Boston, march 15, 2022 (globe newswire) -- aprea therapeutics, inc. (nasdaq: apre), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the three months and year ended december 31, 2021 and provided a business update.
2021-12-13 08:00:00 - Press Release
Aprea Therapeutics Presents Primary Analysis From Phase 2 Trial Of Eprenetapopt + Azacitidine For Post-transplant Maintenance Therapy In Tp53 Mutant Mds And Aml At The 2021 American Society Of Hematology (ash) Annual Meeting
Boston, dec. 13, 2021 (globe newswire) -- aprea therapeutics, inc. (nasdaq: apre), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced updated results from its phase 2 trial evaluating eprenetapopt with azacitidine for post-transplant maintenance therapy in patients with tp53 mutant mds and aml at the 2021 ash annual meeting.
2021-11-08 16:15:00 - Press Release
Aprea Therapeutics Reports Third Quarter 2021 Financial Results And Provides Update On Business Operations
Boston, nov. 08, 2021 (globe newswire) -- aprea therapeutics, inc. (nasdaq: apre), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the three and nine months ended september 30, 2021 and provided a business update.
2021-09-20 16:15:00 - Press Release
Aprea Therapeutics Presents Data From Phase 1/2 Trial Of Eprenetapopt (apr-246) In Advanced Solid Tumors At Esmo Congress 2021
Boston, sept. 20, 2021 (globe newswire) -- aprea therapeutics, inc. (nasdaq: apre), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today presented data at the european society of medical oncology (esmo) congress 2021 from its phase i/ii clinical trial in advanced solid tumors. the trial is evaluating the safety and efficacy of eprenetapopt in combination with pembrolizumab.
Latest News
2022-01-14 11:35:15 - Zacks Investment Research
Aprea Therapeutics, Inc. (APRE) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Aprea Therapeutics, Inc. (APRE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
2021-12-10 16:08:33 - PennyStocks
Got $5 to Spend on Penny Stocks? Check These 4 Out
Got $5 to spend on penny stocks? Take a look at these four for your watchlist The post Got $5 to Spend on Penny Stocks?
2021-12-10 12:16:06 - Zacks Investment Research
Aprea (APRE) Reports FDA Removal of Clinical Hold on Study
The FDA removes its clinical hold on Aprea Therapeutics' (APRE) clinical study evaluating eprenetapopt combination study in lymphoid malignancies.
2021-12-09 12:30:43 - Benzinga
FDA Lifts Clinical Hold On Aprea's Eprenetapopt Trial In Myeloid Malignancies
The FDA removed the full clinical hold on Aprea Therapeutics Inc's (NASDAQ: APRE) trial evaluating the combination of eprenetapopt, with acalabrutinib or with venetoclax and rituximab in lymphoid malignancies. The agency issued a clinical hold on the study in August.
2021-12-09 11:58:02 - Pulse2
Aprea Therapeutics Stock (APRE): Why The Price Increased Today
The stock price of Aprea Therapeutics Inc (NASDAQ: APRE) increased by over 14% during intraday trading today. This is why it happened.
2021-09-21 08:39:11 - Benzinga
Aprea Therapeutics Stock Jumps After Eprenetapopt Combo Data Presentation At ESMO
Aprea Therapeutics Inc (NASDAQ: APRE) presented data at the European Society of Medical Oncology (ESMO) Congress 2021 from its Phase 1/2 trial in advanced solid tumors. The trial is evaluating the safety and efficacy of eprenetapopt in combination with pembrolizumab.
2021-09-20 16:15:00 - GlobeNewsWire
Aprea Therapeutics Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advanced Solid Tumors at ESMO Congress 2021
BOSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today presented data at the European Society of Medical Oncology (ESMO) Congress 2021 from its Phase I/II clinical trial in advanced solid tumors. The trial is evaluating the safety and efficacy of eprenetapopt in combination with pembrolizumab.
2021-09-20 09:57:13 - Zacks Investment Research
Is the Options Market Predicting a Spike in Aprea Therapeutics (APRE) Stock?
Investors need to pay close attention to Aprea Therapeutics (APRE) stock based on the movements in the options market lately.
2021-09-20 09:30:35 - Pulse2
APRE Stock: Why It Increased Today
The stock price of Aprea Therapeutics Inc (NASDAQ: APRE) is trading higher today. This is why it happened.
2021-09-19 10:25:00 - PennyStocks
Best Penny Stocks To Buy? 5 To Watch This Week With Biotech Catalysts
